Arvinas (ARVN) Liabilities and Shareholders Equity (2017 - 2026)
Arvinas (ARVN) posted quarterly Liabilities and Shareholders Equity of $647.5 million for Q1 2026, down 35.32% year-over-year from $1.0 billion in Q1 2025, and down 9.81% quarter-over-quarter from $717.9 million in Q4 2025.
Arvinas (ARVN) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Arvinas' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $647.5 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 35.32% year-over-year to $647.5 million; the TTM figure through Mar 2026 stood at $3.1 billion (down 31.29% YoY), while the FY2025 annual figure was $717.9 million, down 34.22% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $647.5 million, down from $717.9 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $1.5 billion in Q1 2022, with the low at $647.5 million in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2024), against an average of $1.1 billion.
- The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity soared 118.47% in 2022, then plunged 35.32% in 2026.
- Arvinas' Liabilities and Shareholders Equity stood at $1.3 billion in 2022, then rose by 2.82% to $1.3 billion in 2023, then slipped by 16.34% to $1.1 billion in 2024, then slumped by 34.22% to $717.9 million in 2025, then retreated by 9.81% to $647.5 million in 2026.
- Business Quant data shows ARVN's Liabilities and Shareholders Equity at $647.5 million in Q1 2026, $717.9 million in Q4 2025, and $844.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 675.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 675.10 Mn |
| Mar 31, 2026 | 647.50 Mn |
| Dec 31, 2025 | 717.90 Mn |
| Sep 30, 2025 | 844.30 Mn |
| Jun 30, 2025 | 909.30 Mn |
| Mar 31, 2025 | 1.00 Bn |
| Dec 31, 2024 | 1.09 Bn |
| Sep 30, 2024 | 1.17 Bn |
| Jun 30, 2024 | 1.28 Bn |
| Mar 31, 2024 | 1.21 Bn |
| Dec 31, 2023 | 1.30 Bn |
| Sep 30, 2023 | 1.06 Bn |
| Jun 30, 2023 | 1.08 Bn |
| Mar 31, 2023 | 1.18 Bn |
| Dec 31, 2022 | 1.27 Bn |
| Sep 30, 2022 | 1.33 Bn |
| Jun 30, 2022 | 1.41 Bn |
| Mar 31, 2022 | 1.49 Bn |
| Dec 31, 2021 | 1.58 Bn |
| Sep 30, 2021 | 1.60 Bn |